Phase I randomized study of <scp>KHK</scp>4083, an anti‐<scp>OX</scp>40 monoclonal antibody, in patients with mild to moderate plaque psoriasis
Bibliographic record
Abstract
Abstract Background OX 40 ( CD 134) is expressed in lesional but not healthy skin of patients with psoriasis. KHK 4083 is a fully human monoclonal antibody against OX 40. Objective The primary aim of this first‐in‐human phase 1 study was to determine the safety and tolerability of ascending single doses of KHK 4083 in patients with mild to moderate plaque psoriasis. Secondary aims were to determine the pharmacokinetics and immunogenicity of KHK 4083, and an exploratory objective was to assess clinical activity. Methods In phase 1a, single doses of KHK 4083 0.003 and 0.001 mg/kg IV were administered open label in two cohorts (each n = 6). Phase 1b had a multicentre, randomized, double‐blind, placebo‐controlled, ascending single‐dose design in seven cohorts. Randomization was performed 3 : 1 to KHK 4083 ( n = 6) or placebo ( n = 2) within each cohort. Ascending doses of KHK 4083 were 0.03, 0.1, 0.3, 1.0, 3.0 and 10 mg/kg IV , and 1.0 mg/kg SC . Results There were no severe or serious adverse events ( AE s), or discontinuations because of AE s. The most frequent treatment‐related AE s in the 55 patients who received KHK 4083 were mild or moderate chills (9.1%), and infusion/injection site reactions (7.3%). No clinically meaningful or dose‐related changes from baseline in laboratory values, vital signs, ECG recordings or physical examinations were observed. Some KHK 4083 recipients (10/54) developed anti‐ KHK 4083 antibodies following treatment. Mean elimination half‐life ( t 1/2 ) increased with dose, maximum serum concentration increased in a dose‐proportional manner, and area under the serum concentration–time curve increased in a more than dose‐proportional manner with increasing IV dose. Absolute bioavailability following SC administration was 73%. There was some indication of improvement in Psoriasis Area Severity Index ( PASI ) and sPGA scores at the highest IV doses (1.0 and 10 mg/kg) and the SC dose (1.0 mg/kg). The largest PASI 50 response and improvement in sPGA score ≥2 occurred with KHK 4083 1.0 mg/kg SC. Conclusion KHK 4083 administration as a single dose up to 10 mg/kg IV or 1.0 mg/kg SC was generally safe and well tolerated in patients with mild to moderate plaque psoriasis with no dose‐limiting AE s.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".